Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43

Chekhonin, V. P.; Baklaushev, V. P.; Yusubalieva, Gaukhar M.; Belorusova, Anastasia E.; Gulyaev, Mikhail V.; Tsitrin, E. B.; Grinenko, N. F.; Gurina, O. I.; Pirogov, Yu. A.

doi:10.1016/j.nano.2011.05.011

Cited by 56 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, it is generally observed that the presence of targeting ligands over the liposome surface improves the uptake of vesicles by target cancer cells and increases their retention time within tumors. 231,233,239,247,253 In gliomas, angiogenesis seems to be the preferable target area for diagnosis of this cancer. Angiogenesis, the formation of new vessels, is a key process for glioma survival and growth.…”

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

356

238

View full text Add to dashboard Cite

This review summarizes articles that have been reported in literature on liposome-based strategies for effective drug delivery across the blood–brain barrier. Due to their unique physicochemical characteristics, liposomes have been widely investigated for their application in drug delivery and in vivo bioimaging for the treatment and/or diagnosis of neurological diseases, such as Alzheimer’s, Parkinson’s, stroke, and glioma. Several strategies have been used to deliver drug and/or imaging agents to the brain. Covalent ligation of such macromolecules as peptides, antibodies, and RNA aptamers is an effective method for receptor-targeting liposomes, which allows their blood–brain barrier penetration and/or the delivery of their therapeutic molecule specifically to the disease site. Additionally, methods have been employed for the development of liposomes that can respond to external stimuli. It can be concluded that the development of liposomes for brain delivery is still in its infancy, although these systems have the potential to revolutionize the ways in which medicine is administered.

show abstract

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

356

238

View full text Add to dashboard Cite

show abstract

“…Cytotoxicity of free CDDP greatly decreased after encapsulation in nanogels (IC 50 2.5 mg/ml). The experimental model of intracranial glioma 101/8 was designed to test various chemotherapeutic agents and is considered one of the most adequate models of glioblastoma multiforme (Chekhonin et al, 2012). In our experiments, the rate of successful glioma implantation was at least 95%.…”

Section: Resultsmentioning

confidence: 90%

“…This approach is especially important in the case of alkylating platinum-containing cytostatic drugs, which display a pronounced non-specific toxicity (Hartmann & Lipp, 2003). The undesirable side effects of drugs could be significantly reduced by encapsulation of them into liposomes (Chekhonin et al, 2012), micelles (Oberoi et al, 2012), polymeric nanoparticles (Wohlfart et al, 2011;Steiniger et al, 2004) and other nanoparticles (Peer et al, 2007). Nanogels -nanoscale hydrogels based on hydrophilic or amphiphilic polymeric network -are one of the promising nanocontainers for platinum-based drugs (Kabanov & Vinogradov, 2009;Nukolova et al, 2011a).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1

et al. 2014

Self Cite

View full text Add to dashboard Cite

(2015) Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1, Drug Delivery, 22:3, 276-285, DOI: 10.3109/10717544.2013 AbstractTargeted drug delivery for brain tumor treatment is one of the important objectives in nanomedicine. Human glioblastoma is the most frequent and aggressive type of brain tumors. The preferential expression of membrane protein connexin 43 (Cx43) and brain-specific anion transporter (BSAT1) in the tumor and peritumoral area is a key component for targeted drug delivery. The purpose of this study was to design cisplatin-loaded nanogels conjugated with monoclonal antibodies to Cx43 and BSAT1 for treatment of intracranial gliomas 101/8. MRI volumetric analysis of tumor-bearing rats indicated significantly reduced tumor volume with cisplatin-loaded targeted-nanogel treatment compared to other formulations. The median survival of rats treated with targeted nanogels conjugated with specific mAbs against extracellular loops of Cx43 and BSAT1 were 27 and 26.6 days higher than that in control group, respectively. For the first time we demonstrated the efficiency of mAb-targeted cisplatin-loaded nanogels in the experimental model of glioma 101/8. This approach could facilitate the development of new drug delivery systems for the treatment of gliomas.

show abstract

“…102 Moreover, such liposomes have already been used to treat breast cancer. 103 The principal mechanism underlying the interaction between such immunoliposomes and brain cells was demonstrated by Chekhonin et al 104 PEG-treated liposomes containing antibodies to glial fibrillary acid protein (GFAP) on their surface selectively bind to brain astrocytes. This led the authors to conclude that immunoliposomes might be used for targeted delivery of MDs to brain tumors.…”

Section: Liposomesmentioning

confidence: 99%

Nanoscale drug delivery systems and the blood–brain barrier

Alyautdin¹,

Khalin²,

Nafeeza³

et al. 2014

IJN

121

View full text Add to dashboard Cite

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate architecture of its endothelium coupled with multiple specific transport systems expressed on the surface of endothelial cells (ECs) in the brain’s vasculature. When the stringent control of the BBB is disrupted, such as following EC damage, substances that are safe for peripheral tissues but toxic to neurons have easier access to the central nervous system (CNS). As a consequence, CNS disorders, including degenerative diseases, can occur independently of an individual’s age. Although the BBB is crucial in regulating the biochemical environment that is essential for maintaining neuronal integrity, it limits drug delivery to the CNS. This makes it difficult to deliver beneficial drugs across the BBB while preventing the passage of potential neurotoxins. Available options include transport of drugs across the ECs through traversing occludins and claudins in the tight junctions or by attaching drugs to one of the existing transport systems. Either way, access must specifically allow only the passage of a particular drug. In general, the BBB allows small molecules to enter the CNS; however, most drugs with the potential to treat neurological disorders other than infections have large structures. Several mechanisms, such as modifications of the built-in pumping-out system of drugs and utilization of nanocarriers and liposomes, are among the drug-delivery systems that have been tested; however, each has its limitations and constraints. This review comprehensively discusses the functional morphology of the BBB and the challenges that must be overcome by drug-delivery systems and elaborates on the potential targets, mechanisms, and formulations to improve drug delivery to the CNS.

show abstract

Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43

Cited by 56 publications

References 13 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1

Nanoscale drug delivery systems and the blood–brain barrier

Contact Info

Product

Resources

About

Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43

Cited by 56 publications

References 13 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1

Nanoscale drug delivery systems and the blood&ndash;brain barrier

Contact Info

Product

Resources

About

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Nanoscale drug delivery systems and the blood–brain barrier